Mabpharm Limited (HK:2181) has released an update.
Mabpharm Limited has announced that their biologic drug, CMAB008 (infliximab for injection), has received approval from the Ministry of Health of Peru for treating six inflammatory conditions, including ulcerative colitis and rheumatoid arthritis. CMAB008 is the first infliximab developed and approved in China, promising better affinity and longer lasting effects compared to existing anti-TNF drugs, and it is now covered by China’s medical insurance program. This approval marks a significant milestone for the company, potentially offering a more cost-effective treatment option for patients.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.
